D. Lanz

Oxaliplatin, Irinotecan and Capecitabine (OCX) for First-Line Treatment of Advanced/Metastatic Colorectal Cancer: A Phase I Trial (SAKK 41/03)

T. Ruhstaller, R. Cathomas, R. Popescu, 2010, Oncology Research and Treatment.

The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in first-line treatment of metastatic colorectal cancer (MCC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK).

R. Herrmann, M. Borner, A. Roth, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK.

T. Ruhstaller, M. Borner, A. Kappeler, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity.

R. Herrmann, J. Bernhard, M. Borner, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and Tolerability of Capecitabine with Weekly Paclitaxel for Patients with Metastatic Breast Cancer: A Phase II Report of the SAKK

C. Rochlitz, S. Aebi, P. Ballabeni, 2007, Oncology.